“…This is most clearly demonstrated by the renoprotection which is seemingly afforded with HMG CoA reductase inhibitors [102,103,104]. Interestingly, the majority of the AGE inhibitors assessed in this review (table 1) have been reported to improve lipid profiles in diabetic patients [99], as well as in experimental models of diabetic complications [31, 33, 64, 67, 69, 79, 105, 106]. Effects of RAS blockers, sRAGE and TZDs in plasma lipids have not been previously reported.…”